BRIEF-Pfizer And BioNtech Announce Topline Results From Trial Of Covid-19 Vaccine In Children 5 To 11 Years

* PFIZER AND BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS FROM PIVOTAL TRIAL OF COVID-19 VACCINE IN CHILDREN 5 TO 11 YEARS

* PFIZER - IN PARTICIPANTS 5 TO 11 YEARS OF AGE, VACCINE WAS SAFE, WELL TOLERATED AND SHOWED ROBUST NEUTRALIZING ANTIBODY RESPONSES * PFIZER - SARS-COV-2–NEUTRALIZING ANTIBODY GMT WAS 1,197.6 SHOWING STRONG IMMUNE RESPONSE IN COHORT OF CHILDREN ONE MONTH AFTER SECOND DOSE

* PFIZER - RESULTS IN CHILDREN UNDER 5 YEARS OF AGE ARE EXPECTED AS SOON AS LATER THIS YEAR * PFIZER - ANTIBODY RESPONSES IN CHILDREN GIVEN 10 MICROGRAM DOSES WERE COMPARABLE TO THOSE IN PEOPLE 16 TO 25 YEARS IMMUNIZED WITH 30 MICROGRAM DOSES

* PFIZER - TOPLINE READOUTS FOR OTHER TWO AGE COHORTS FROM TRIAL – CHILDREN 2-5 YRS AND CHILDREN 6 MONTHS TO 2 YRS – ARE EXPECTED AS SOON AS Q4 Source text: https://refini.tv/3Cwwc4z